Prenoxdiazine

Prenoxdiazine
Clinical data
Trade names	Libexin
AHFS/Drugs.com	International Drug Names
ATC code	R05DB18 (WHO) ;
Identifiers
	IUPAC name 1-[2-[3-(2,2-diphenylethyl)-1,2,4-oxadiazol-5-yl]ethyl]piperidine;
CAS Number	47543-65-7 ; HCl: 982-43-4 ;
PubChem CID	120508;
ChemSpider	107586 ;
UNII	S491HH391H; HCl: 390WW7V7MZ ;
CompTox Dashboard (EPA)	DTXSID10197192 ;
Chemical and physical data
Formula	C23H27N3O
Molar mass	361.489 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES n1c(onc1CC(c2ccccc2)c3ccccc3)CCN4CCCCC4;
	InChI InChI=1S/C23H27N3O/c1-4-10-19(11-5-1)21(20-12-6-2-7-13-20)18-22-24-23(27-25-22)14-17-26-15-8-3-9-16-26/h1-2,4-7,10-13,21H,3,8-9,14-18H2 ; Key:PXZDWASDNFWKSD-UHFFFAOYSA-N ;
	(verify)

Prenoxdiazine (marketed as Libexin) is a cough suppressant.^[1] It acts peripherally by desensitizing the pulmonary stretch receptors. Therefore, there's a reduction of cough impulses originating in the lungs. Prenoxdiazine is indicated in cough of bronchial origin.

References

^ Csürös L (1989). "Fifteen years of experience on the use of Libexin tablets". Therapia Hungarica. 37 (1): 50–4. PMID 2667194.

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.

[1] Csürös L (1989). "Fifteen years of experience on the use of Libexin tablets". Therapia Hungarica. 37 (1): 50–4. PMID 2667194.

[1]